Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansoh Pharmaceutical Group Company Limited has announced that its B7-H3-targeted antibody-drug conjugate, HS-20093, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration for treating small cell lung cancer. This promising development follows a licensing agreement with GlaxoSmithKline, which is conducting global trials of the drug. Such advancements could significantly impact Hansoh’s market position and attract investor interest.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.